药效团
帕博西利布
对接(动物)
细胞周期蛋白依赖激酶6
虚拟筛选
细胞周期蛋白依赖激酶4
激酶
化学
细胞周期
细胞周期蛋白依赖激酶
生物化学
计算生物学
作者
Ni Made Pitri Susanti,Sophi Damayanti,Rahmana Emran Kartasasmita,Daryono H. Tjahjono
标识
DOI:10.3390/ijms222413423
摘要
The G1 phase of cell cycle progression is regulated by Cyclin-Dependent Kinase 4 (CDK4) as well as Cyclin-Dependent Kinase 6 (CDK6), and the acivities of these enzymes are regulated by the catalytic subunit, cyclin D. Cell cycle control through selective pharmacological inhibition of CDK4/6 has proven to be beneficial in the treatment of estrogen receptor-positive (ER-positive) breast cancer, particularly improving the progression-free survival of patients. Thus, targeting specific inhibition on CDK4/6 is bound to increase therapeutic efficiency. This study aimed to obtain CDK4/6 inhibitors through a pharmacophore-based virtual screening of the ZINC15 purchasable compound database using the in silico method. The pharmacophore model was designed based on the FDA-approved cdk4/6 inhibitor structures, and molecular docking was performed to further screen the hit compounds obtained. A total of eight compounds were selected based on docking results and interactions with CDK4 and CDK6, using palbociclib as the reference drug. According to the results, the compounds of ZINC585292724 and ZINC585291674 were the best compounds based on free binding energy, as well as hydrogen bond stability, and, therefore, exhibit potential as starting points in the development of CDK4/6 inhibitors.
科研通智能强力驱动
Strongly Powered by AbleSci AI